• Kyodo

  • SHARE

Nobel laureate Tasuku Honjo said he will make a decision as early as July on whether to sue Ono Pharmaceutical Co. to demand a hike in the licensing fee for cancer drug Opdivo, which was developed based on his research.

“It would lead to serious trouble in the future if this case is settled in an ambiguous way,” Honjo said in a recent interview, hinting at his intention to continue negotiating with the drugmaker.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)